A WHIM satisfactorily addressed.
In this issue of Blood, McDermott et al present the intriguing, clinically relevant, and perhaps unexpected findings for the efficacy and safety of long-term administration of low-dose plerixafor treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome.
INDIANA UNIVERSITY SCHOOL OF MEDICINE.
Hal E
HE
Broxmeyer
D001596:Benzylamines; D000080027:Cyclams; D005260:Female; D006571:Heterocyclic Compounds / Q000627:therapeutic use*; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy*; D008297:Male; D000081207:Primary Immunodeficiency Diseases; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors*; D014860:Warts / Q000188:drug therapy*
D001596:Benzylamines; C527276:CXCR4 protein, human; D000080027:Cyclams; D006571:Heterocyclic Compounds; D019718:Receptors, CXCR4; C088327:plerixafor